We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Cellmid Signs Evaluation and Option to License Agreement with Zoetis

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Cellmid Signs Evaluation and Option to License Agreement with Zoetis"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:

Cellmid Limited has signed an agreement with Zoetis for the evaluation and option to license one of Cellmid’s anti-midkine antibodies (MK antibody) for therapeutic use in companion animals.

Cellmid’s proprietary MK antibodies have previously been shown to be effective in animal models of a number of diseases.

Zoetis has extensive experience in the development and commercialization of animal health products and will evaluate the performance of Cellmid’s MK antibody in their proprietary models with the view to license.

The agreement is exclusive for the use of Cellmid’s MK-antibody in animals. The terms of the agreement include upfront and exclusivity payments until such time as the option to license is exercised by Cellmid’s partner. Additional financial details of the agreement are not disclosed.